Robert Azelby

Robert Azelby currently serves as a Member of the Board of Directors for multiple companies, including Terns Pharmaceuticals, Cardinal Health, Autolous Therapeutics, and ADC Therapeutics, demonstrating extensive experience in corporate governance within the biopharmaceutical sector. Previously, Robert held leadership roles such as President and Chief Executive Officer at both Eliem Therapeutics and Alder Biopharmaceuticals, overseeing significant organizational developments and strategic acquisitions. Notably, Robert was instrumental in commercial operations at Juno Therapeutics as EVP, Chief Commercial Officer, contributing to the company's successful acquisition by Celgene. Robert holds an MBA from Harvard Business School and a BA in Economics and Religious Studies from the University of Virginia.